Kirn David sold 58,333 shares of 4D Molecular Therapeutics at $13.90 per share, a transaction equal to about 7.1% of the prior holding. Investors can see that 767,486 shares remained in the reported position after the sale, while transaction code S classifies the activity as an open-market sale.
Key Highlights
- Kirn David held 767,486 4D Molecular Therapeutics shares after the transaction.
- The sale represented about 7.1% of Kirn David’s prior shareholding.
- Transaction code S identifies the activity as an open-market sale dated 14 September 2026.
Kirn David sold 58,333 shares of 4D Molecular Therapeutics at $13.90 per share. The transaction involved the company’s stock and reduced the reported position while leaving a substantial holding in place.
Sale Details and Remaining Holding
The transaction date was 14 September 2026. The reported transaction code was S, which denotes an open-market sale in the Form 4 classification system. After the sale, Kirn David owned 767,486 shares of 4D Molecular Therapeutics. The transaction was recorded in connection with Kirn David’s position in the company. The sale was measured against the shares held before the transaction. That comparison puts the transaction at about 7.1% of Kirn David’s prior shareholding.
FAQs
Q: How many 4D Molecular Therapeutics shares did Kirn David sell?
A: Kirn David sold 58,333 4D Molecular Therapeutics shares. The sale price was $13.90 per share, according to the reported insider transaction.
Q: How many shares did Kirn David retain after the sale?
A: Kirn David owned 767,486 4D Molecular Therapeutics shares after the transaction. The remaining balance was reported following the sale.
Q: What does transaction code S mean for Kirn David’s transaction?
A: Code S identifies an open-market sale in the Form 4 transaction classification. The transaction occurred on 14 September 2026 and represented about 7.1% of the prior holding.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.